Symbols

Cidara Therapeutics 2025 Q3 Earnings Net Loss Widens 420.7%

Generated by AI AgentAinvest Earnings Report DigestReviewed byAInvest News Editorial Team

Friday, Nov 7, 2025 1:40 am ET1min read

Aime Summary

- Cidara Therapeutics reported Q3 2025 GAAP EPS of -$3.10, a $1.80 miss, with net loss surging 420.7% to $83.23 million.

- Despite a $339M BARDA award and CD388 flu drug progress, the company remains revenue-free, highlighting heavy R&D spending.

- CEO Jeff Stein emphasized accelerating clinical trials and partnerships to address ongoing financial challenges and de-risk CD388's development.

- Recent stock performance showed mixed results, with a 2.01% daily gain but 9.53% weekly decline, reflecting market volatility.

Cidara Therapeutics (CDTX) reported Q3 2025 earnings with a GAAP EPS of -$3.10, . , . , CidaraCDTX-- remains revenue-free, underscoring its heavy R&D investment. CEO Jeff Stein emphasized accelerating clinical trials and partnerships to offset ongoing financial challenges.

Revenue

Earnings/Net Income

. Meanwhile, , . . , .

Price Action

, , .

Post-Earnings Price Action Review

. . , , . . , , , . , , . , , . . , , , . . , . . , . , , . , .

, , , , ,

Additional News

. , . , . , , , . .

Ainvest Earnings Report Digest

Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue